Critical Limb Ischemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Critical Limb Ischemia – Pipeline Review, H2 2017’, provides an overview of the Critical Limb Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia

The report reviews pipeline therapeutics for Critical Limb Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Critical Limb Ischemia therapeutics and enlists all their major and minor projects

The report assesses Critical Limb Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Critical Limb Ischemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AnGes MG Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kang Stem Biotech Co Ltd

Kasiak Research Pvt Ltd

Neurofx Inc

Nissan Chemical Industries Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Symic Biomedical Inc

TikoMed AB

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Critical Limb Ischemia - Overview 6

Critical Limb Ischemia - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Critical Limb Ischemia - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Critical Limb Ischemia - Companies Involved in Therapeutics Development 23

AnGes MG Inc 23

apceth Biopharma GmbH 23

Athersys Inc 24

BiogenCell Ltd 24

Caladrius Biosciences Inc 24

Cynata Therapeutics Ltd 25

Hemostemix Inc 25

Histocell SL 26

ID Pharma Co Ltd 26

Integene International Holdings LLC 26

Juventas Therapeutics Inc 27

Kang Stem Biotech Co Ltd 27

Kasiak Research Pvt Ltd 27

Neurofx Inc 28

Nissan Chemical Industries Ltd 28

Pharmicell Co Ltd 29

Pluristem Therapeutics Inc 29

ReNeuron Group Plc 30

Symic Biomedical Inc 30

TikoMed AB 31

U.S. Stem Cell Inc 31

VESSL Therapeutics Ltd 31

ViroMed Co Ltd 32

Critical Limb Ischemia - Drug Profiles 33

ACP-01 - Drug Profile 33

AdipoCell - Drug Profile 36

Alecmestencel-T - Drug Profile 39

ASCT-01 - Drug Profile 40

beperminogene perplasmid - Drug Profile 41

BGC-101 - Drug Profile 46

Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 47

Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases - Drug Profile 48

Cellgram-CLI - Drug Profile 49

CLBS-12 - Drug Profile 50

DVC-10101 - Drug Profile 51

Gene Therapy for Critical Limb Ischemia - Drug Profile 53

HC-016 - Drug Profile 54

JVS-100 - Drug Profile 55

NFx-101 - Drug Profile 60

NK-104 NP - Drug Profile 61

PF-05285401 - Drug Profile 62

PLX-PAD - Drug Profile 74

Procell - Drug Profile 85

Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile 86

Refacell-CLI - Drug Profile 87

Rejuveinix - Drug Profile 88

ReN-009 - Drug Profile 89

SB-030 - Drug Profile 91

Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 93

Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 95

Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 96

Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 97

TM-700 - Drug Profile 98

TXA-302 - Drug Profile 99

VM-202 - Drug Profile 100

Critical Limb Ischemia - Dormant Projects 104

Critical Limb Ischemia - Discontinued Products 106

Critical Limb Ischemia - Product Development Milestones 107

Featured News & Press Releases 107

Appendix 116

Methodology 116

Coverage 116

Secondary Research 116

Primary Research 116

Expert Panel Validation 116

Contact Us 116

Disclaimer 117

List of Tables

List of Tables

Number of Products under Development for Critical Limb Ischemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Critical Limb Ischemia – Pipeline by AnGes MG Inc, H2 2017

Critical Limb Ischemia – Pipeline by apceth Biopharma GmbH, H2 2017

Critical Limb Ischemia – Pipeline by Athersys Inc, H2 2017

Critical Limb Ischemia – Pipeline by BiogenCell Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Caladrius Biosciences Inc, H2 2017

Critical Limb Ischemia – Pipeline by Cynata Therapeutics Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Hemostemix Inc, H2 2017

Critical Limb Ischemia – Pipeline by Histocell SL, H2 2017

Critical Limb Ischemia – Pipeline by ID Pharma Co Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Integene International Holdings LLC, H2 2017

Critical Limb Ischemia – Pipeline by Juventas Therapeutics Inc, H2 2017

Critical Limb Ischemia – Pipeline by Kang Stem Biotech Co Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Kasiak Research Pvt Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Neurofx Inc, H2 2017

Critical Limb Ischemia – Pipeline by Nissan Chemical Industries Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Pharmicell Co Ltd, H2 2017

Critical Limb Ischemia – Pipeline by Pluristem Therapeutics Inc, H2 2017

Critical Limb Ischemia – Pipeline by ReNeuron Group Plc, H2 2017

Critical Limb Ischemia – Pipeline by Symic Biomedical Inc, H2 2017

Critical Limb Ischemia – Pipeline by TikoMed AB, H2 2017

Critical Limb Ischemia – Pipeline by U.S. Stem Cell Inc, H2 2017

Critical Limb Ischemia – Pipeline by VESSL Therapeutics Ltd, H2 2017

Critical Limb Ischemia – Pipeline by ViroMed Co Ltd, H2 2017

Critical Limb Ischemia – Dormant Projects, H2 2017

Critical Limb Ischemia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Critical Limb Ischemia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Critical Limb Ischemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports